Home/Filings/8-K/0001213900-26-007987
8-K//Current report

OSR Holdings, Inc. 8-K

Accession 0001213900-26-007987

$OSRHCIK 0001840425operating

Filed

Jan 26, 7:00 PM ET

Accepted

Jan 27, 9:26 AM ET

Size

262.2 KB

Accession

0001213900-26-007987

Research Summary

AI-generated summary of this filing

Updated

OSR Holdings Completes Acquisition of Woori IO via Share Exchange

What Happened

  • OSR Holdings, Inc. (OSRH) reported on Form 8-K (filed Jan 27, 2026) that its subsidiary OSR K., Ltd. (“OSRK”) completed the share exchange contemplated by the Share Exchange Agreement dated October 13, 2025.
  • Through the exchange, Woori IO Co., Ltd. (“WORIO”), a South Korea–based medical device developer focused on non‑invasive biosensing for glucose monitoring and related health parameters, became a wholly owned subsidiary of OSRK and an indirect subsidiary of OSR Holdings.

Key Details

  • Exchange ratio: each issued and outstanding WORIO share was exchanged for 0.948832 shares of OSRK.
  • Aggregate issuance: OSRK issued 84,338 newly issued OSRK shares in exchange for 88,891 WORIO shares.
  • Structure: the acquisition was effected by issuing equity interests of OSRK (the subsidiary); no shares of OSR Holdings’ common stock were issued.
  • Prior disclosure: the transaction was previously disclosed in the Company’s Form 8-K filed Oct 16, 2025.

Why It Matters

  • The deal brings WORIO’s non‑invasive glucose monitoring technology into OSR’s corporate structure, meaning future consolidated financials and disclosures will include WORIO’s results and activities.
  • Because the acquisition was completed via subsidiary equity (not parent stock or cash), it changes the subsidiary ownership structure without diluting OSR Holdings’ common stock.
  • Retail investors should watch for upcoming disclosures on integration plans, any material impacts on revenue or R&D timelines, and how OSR intends to commercialize or fund WORIO’s technology.